Top Stories Friday, February 3, 2017 Stemline Therapeutics has admitted it learnt of a death in its phase 2 cancer trial the day before it went ahead with a $45 million stock offering. The admission follows a report in The Street about the death—the third from the same side effect—that wiped more than 40% off Stemline’s stock price. Friday, February 3, 2017 Boosted by a fresh $30 million tranche of funding, Tarveda Therapeutics will start phase 2 trials of its lead drug for advanced neuroendocrine tumors and small cell lung cancer early next year, according to CEO Drew Fromkin. Friday, February 3, 2017 Targovax has posted two-year survival data from a phase 1/2 trial of TG01 in resected pancreatic cancer patients. More than 60% of participants were alive two years after starting treatment, sparking a 40% surge in the stock price of Targovax. Thursday, February 2, 2017 In this week's EuroBiotech Report, Novo invests in U.K. R&D site, Arix files for £100 million IPO, AstraZeneca talks up Brexit opportunities and more. Friday, February 3, 2017 In this week's FiercePharmaAsia wrap-up, FibroGen and AstraZeneca prepare NDA in China for an anemia drug, Astellas buys rights to Auration's ruptured eardrum med, and Takeda promises to contain yearly drug price increases under 10%. Thursday, February 2, 2017 Genentech's Rick Fair leaves the company to join Bellicum as CEO, Juno Therapeutics taps Corsee Sanders as new development operations head who oversees clinical trials, and Sanofi poaches Kathleen Tregoning from Biogen as its new EVP of external affairs. Plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Destination Medical Center. | | | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | After a recent trial setback, Auris Medical says it has expanded its pipeline with intranasal betahistine in Meniere's disease and vestibular vertigo. Statement Bionomics has gained a milestone bonus payment from Merck after starting a phase 1 test in Alzheimer's. Release Axovant Sciences has taken out $55 million in a venture debt financing deal from Hercules Capital. Statement | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! PEGS: The Essential Protein Engineering Summit May 1-5, 2017 | Boston, MA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA BIO CEO & Investor Conference February 13 – 14, 2017 | The Waldorf Astoria, New York, NY CBI’s Abuse Deterrent Formulations Summit March 7-8, 2017 | Alexandria, VA |
